SEC Form 4
Akebia Therapeutics, Inc. (AKBA) insider trading
In the 12 months to Oct 26, 2026, one AKBA insider reported open-market purchases of $86.6K across 1 filing; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $86.6K
- 1 filing · John P. Butler, CEO and President
Who traded AKBA, and when
- Purchase
AKBA daily close from Oct 27, 2025 to Oct 26, 2026, between $0.56 and $3.17, last $0.64. 0 sale and 1 purchase filings by 1 insider, marked at their filing dates. John P. Butler, CEO and President: bought $86.6K across 1 filing, first filed Mar 5, 2026, last Mar 5, 2026.
Largest mark · tap a row for others
John P. Butler · CEO and President
Purchase $86,588
69,270 shares at $1.25 avg
Filed Mar 5, 2026 · traded Mar 4
Close on filing date $1.19
John P. Butler · CEO and President
CEO and President
$86.6K boughtOpen-market trades
1 filing in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| John P. Butler | CEO and President | — | $86.6K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | John P. Butler CEO and President | Purchase | 69,270 | $1.25 | $86.6K | 3,367,064 |
GET /stocks/filings/vX/form-4?tickers=AKBA&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"AKBA"
],
"issuer_cik": "0001517022",
"owner_cik": "0001591467",
"accession_number": "0001591467-26-000003",
"form_type": "4",
"filing_date": "2026-03-05",
"period_of_report": "2026-03-04",
"issuer_name": "Akebia Therapeutics, Inc.",
"issuer_trading_symbol": "AKBA",
"owner_name": "Butler John P.",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "CEO and President",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-03-04",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 69270,
"transaction_price_per_share": 1.25,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 3367064,
"transaction_value": 86587.5,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The reporting person's purchase of Akebia Therapeutics, Inc. (\"Akebia\") common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 69,270 shares, with the reporting person's sale of 341,305 shares of Akebia common stock at a price of $1.39 per share on February 2, 2026 pursuant to an automatic sell-to-cover instruction solely to cover applicable withholding taxes in connection with the vesting of the reporting person's RSUs granted on January 31, 2023, 2024 and 2025. The reporting person has paid Akebia, upon settlement of the sale, $9,664.60 representing the full amount of the profit realized in connection with the short-swing transaction."
},
{
"id": "F2",
"description": "The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."
}
]
}
]
}
// trimmed to 1 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 30 records
- Option exercises1 record
- Tax withholding (sold to cover)16 records
- Grants and awards13 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Akebia Therapeutics, Inc.'s CEO sold stock?
No. John P. Butler (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is AKBA’s insider data?
These are AKBA Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track AKBA insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for AKBA every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.